ViroGates A/S
CSE:VIRO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ViroGates A/S
Net Income
ViroGates A/S
Net Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
V
|
ViroGates A/S
CSE:VIRO
|
Net Income
-kr12.4m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
GN Store Nord A/S
CSE:GN
|
Net Income
kr1.6B
|
CAGR 3-Years
13%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
|
Ambu A/S
CSE:AMBU B
|
Net Income
kr544m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
2%
|
CAGR 10-Years
N/A
|
|
|
Demant A/S
CSE:DEMANT
|
Net Income
kr3.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
20%
|
CAGR 10-Years
7%
|
|
ViroGates A/S
Glance View
ViroGates A/S develops and markets prognostic products for the healthcare sector. Its develops a product line suPARnostic, which measures the amount of amount of soluble urokinase Plasminogen Activator Receptor protein (suPAR) in human blood. The plasma level of suPAR reflects immune activation and is increased in such infectious diseases as HIV-1-infection, malaria, tuberculosis, Streptococcus pneumonia bacteraemia, sepsis, pneumococcal pneumonia and bacterial and viral CNS infection. Also, high suPAR levels are associated with increased inflammation, disease progression and risk of mortality. Thus, measuring suPAR levels serves as a marker to determine chances for survival upon hospital admission, as well as for monitoring for prevention of disease progression and earlier intervention time point. suPARnostic has two versions: Quantitative Point of Care Quick Triage test, which serves for patient triage in acute care, and Quantitative ELISA Assay that aims at clinical routine use.
See Also
What is ViroGates A/S's Net Income?
Net Income
-12.4m
DKK
Based on the financial report for Sep 30, 2025, ViroGates A/S's Net Income amounts to -12.4m DKK.
What is ViroGates A/S's Net Income growth rate?
Net Income CAGR 5Y
10%
Over the last year, the Net Income growth was 6%. The average annual Net Income growth rates for ViroGates A/S have been -1% over the past three years , 10% over the past five years .
